Cognition Therapeutics (CGTX) Other Gross PP&E Adjustments (2020 - 2026)
Cognition Therapeutics (CGTX) reported Other Gross PP&E Adjustments of -$507000.0 for Q1 2026, up 29.09% year-over-year from -$392746.5 in Q1 2025, and up 10.27% on a QoQ basis from -$565000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$507000.0 in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 29.09% year-over-year to -$507000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$507000.0 (up 29.09% YoY) and the FY2025 annual result came in at -$565000.0, down 256.08% from the prior year.
- Other Gross PP&E Adjustments rose to -$507000.0 in Q1 2026 per CGTX's latest filing, from -$565000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $362000.0 in Q4 2024 and bottomed at -$1.5 million in Q3 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$715000.0 (2025), against an average of -$626705.9.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments soared 307.58%; it then sank 256.08% in 2025.
- Tracing CGTX's Other Gross PP&E Adjustments over 5 years: stood at $66000.0 in 2022, then surged by 307.58% to $269000.0 in 2023, then surged by 34.57% to $362000.0 in 2024, then slumped by 256.08% to -$565000.0 in 2025, then gained by 10.27% to -$507000.0 in 2026.
- Per Business Quant, the three latest CGTX Other Gross PP&E Adjustments figures stand at -$507000.0 (Q1 2026), -$565000.0 (Q4 2025), and -$512000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -507,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -507,000.00 |
| Mar 31, 2026 | -507,000.00 |
| Dec 31, 2025 | -565,000.00 |
| Dec 31, 2025 | -565,000.00 |
| Sep 30, 2025 | -512,000.00 |
| Sep 30, 2025 | -512,000.00 |
| Jun 30, 2025 | -673,000.00 |
| Jun 30, 2025 | -673,000.00 |
| Mar 31, 2025 | -715,000.00 |
| Mar 31, 2025 | -715,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | -772,000.00 |
| Sep 30, 2024 | -772,000.00 |
| Jun 30, 2024 | -798,000.00 |
| Jun 30, 2024 | -798,000.00 |
| Mar 31, 2024 | -992,000.00 |
| Mar 31, 2024 | -992,000.00 |
| Dec 31, 2023 | 269,000.00 |
| Dec 31, 2023 | 269,000.00 |
| Sep 30, 2023 | -834,000.00 |
| Sep 30, 2023 | -834,000.00 |
| Jun 30, 2023 | -904,000.00 |
| Jun 30, 2023 | -904,000.00 |
| Mar 31, 2023 | -1.01 Mn |
| Mar 31, 2023 | -1.01 Mn |
| Dec 31, 2022 | 66,000.00 |
| Dec 31, 2022 | 66,000.00 |
| Sep 30, 2022 | -1.51 Mn |
| Sep 30, 2022 | -1.51 Mn |
| Jun 30, 2022 | -877,000.00 |
| Jun 30, 2022 | -877,000.00 |
| Mar 31, 2022 | -688,000.00 |
| Mar 31, 2022 | -688,000.00 |
| Dec 31, 2021 | 470,000.00 |
| Dec 31, 2021 | 470,000.00 |
| Dec 31, 2020 | 697,000.00 |
| Dec 31, 2020 | 697,000.00 |